Closed Trial – status update

MITO 16b-MaNGOov2b

A multicenter phase III randomized study with second line chemotherapy ± bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line

Trial setting: **Second line OC**

Sponsor: **NCI Naples**

Lead groups: **MITO MaNGO**

Final No. of patients: **406**

Timeline: **FPI: 12/2013**

LPI: 11/2016

Publications: **Q1 2018 primary**

Planned substudies:

translational

CBDCA AUC5 + PAC 175 mg/m2 q3w
or
CBDCA AUC4, d1 + GEM 1000mg /m2, d1&8 q3w
or
CBDCA AUC5+PLD 30mg/m2 q4w

- **Plat sensitive OC**
- **Previous Bevacizumab**
- **ECOG 0-2**
- **Availability of samples for translational res.**
- **No Beva contraindications**

R

CBDCA AUC5 + PAC 175 mg/m2 q3w
Plus bevacizumab 15mg/kg q3w**
or
CBDCA AUC4, d1 + GEM 1000mg /m2, d1&8 q3w
Plus bevacizumab 15mg/kg q3w
or
CBDCA AUC5+PLD 30mg/m2 q4w
Plus bevacizumab 10mg/kg q2w

Ongoing Trials – status update

MITO 23; MANGO-OV2b

Randomized phase III trial on Trabectedin (ET 743) vs clinician's choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients

Trial setting: Patient BRCA mutated or BRCAness phenotype with recurrent ovarian, primary peritoneal or fallopian tube cancers

Sponsor(s): INT - Milan

Planned No. of patients: 244

Current accrual: 65